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Introduction 
As a result of  recent findings from the National Eye In-
stitute’s Age-Related Eye Disease 
Study (AREDS) and the Veterans 
Lutein Antioxidant Supplementation 
Trial (LAST) Study, interventions for 
patients with atrophic age-related 
macular degeneration now include 
recommendations for dietary 
supplements in an effort to slow, 
halt or reverse the disease’s pro-
gression. The AREDS formula-
tion consists of  500mg vitamin C, 
400IU vitamin E, 80mg zinc, 2mg 
copper and 15,000IU beta-caro-
tene.1 LAST participants received 
10mg lutein daily, or 10mg lutein 
plus a broad-spectrum formulation 
of  antioxidants, vitamins and  
minerals.2 AREDS and LAST  
formulations both decreased the 
vision loss in patients with mod-
erate and severe AMD, although 
long-term risk reduction with 
lutein could not be evaluated due 
to the small sample size and short 
timeframe of  the LAST study. 
Intervention with lutein in LAST 
also led to improved vision in 
patients with mild, moderate and 
severe forms of  AMD, presum-
ably by increasing macular pigment 
optical density (MPOD).2 More  
recent studies demonstrate the 
utility of  lutein and zeaxanthin 
supplementation in the fight 
against atrophic AMD, using such 
methods as mfERG,3 fundus auto-
fluorescence,4 and heterochromatic 
flicker photometry.5 The Zeaxan-
thin and Visual Function Study 
compared lutein to zeaxanthin, to 
lutein plus zeaxanthin supplemen-
tation using kinetic visual fields, 
foveal shape discrimination and het-
erochromatic flicker photometry.6
CASE REPORT
One optometrist’s personal experience with age-related  
macular degeneration (AMD) and nutritional supplementation
Contexte : La dégénérescence maculaire 
liée à l’âge (DMLA) est la principale cause 
de cécité dans les sociétés occidentales 
vieillissantes et entraîne plus de 50 % du 
total des incapacités visuelles aux États-
Unis. Ce rapport décrit l’histoire d’un 
optométriste de 66 ans qui lutte avec 
succès contre la DMLA depuis 25 ans. 
Rapport de cas : Acuité visuelle 
et série de photographies de la 
rétine de 1983 à 2009 à mesure que 
diverses modifications des habitudes 
alimentaires et des habitudes de vie non 
alimentaires ont été mises en œuvre. 
Après avoir commencé à prendre des 
suppléments nutritionnels à base de 
lutéine environ 15 ans après le diagnostic, 
l’optométriste a vu son acuité visuelle 
selon l’échelle de Snellen s’améliorer 
dans son œil droit pour passer de 20/40 
à 20/25, combinée à une amélioration 
subjective de la distorsion, mais elle a 
éventuellement régressé à 20/70-20/80 
accompagnée d’une augmentation de 
la métamorphopsie. Dans l’œil gauche, 
l’acuité visuelle de 20/30 au début s’est 
améliorée à 20/15 et est demeurée stable 
à 20/20 accompagnée d’une résolution 
complète de la métamorphopsie et d’une 
résolution quasi complète du scotome 
parafovéal. Des photographies du fond 
de l’œil démontrent une réduction du 
dénombrement des drusens mous et 
durs au fil du temps dans chaque rétine et 
une repigmentation parafovéale possible 
de zones atrophiques après l’ajout 
ultérieur de zéaxanthine à plus forte dose. 
Conclusions : La DMLA est une maladie 
qui répond à la nutrition. Le caroténoïde, 
la lutéine et la zéaxanthine semblent 
constituer des éléments thérapeutiques 
particulièrement robustes de formulations 
de suppléments nutritionnels.
mots clés : Dégénérescence maculaire 
liée à l’âge, lutéine, zéaxanthine.
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Case Report
An OD’s Struggle
A then 41-year old Caucasian male 
optometrist (one of  this report’s 
authors, TP) was diagnosed 
with atrophic AMD in 1983 and 
initiated a plethora of  over-the-
counter supplements, including the 
original pre-lutein Bausch & Lomb 
Ocuvite and Ocuvite Extra, Alcon 
ICAPS and ICAPS Plus, vitamin 
E, rose hip and Centrum. Baseline 
fundus photos taken in 1983 (Fig-
ure 1a) and 1988 (Figure 1b) demon-
strated an increasing number and 
size of  drusen over this five-year 
period despite this aggressive di-
etary supplement regimen.  During 
the next 10 years, TP continued to 
monitor the disease and to take the 
supplements in an effort to slow 
disease progression.  
In September 1997 at the age 
of  55, TP reported the develop-
ment of  metamorphopsia OU and 
a parafoveal scotoma was dis-
covered on automated perimetry 
OS (not shown).  Photos taken 
in 1998 demonstrated numerous 
intermediate-sized, and some large, 
soft, confluent drusen bilaterally 
(Figure 1c). During a consultation 
with an ophthalmologist in 1998, 
TP was told he may not be able to 
practice optometry in one-to-two 
years based on his fundus findings. 
The metamorphopsia he reported 
was accompanied by a reduction 
in visual acuity that appeared to 
support the ophthalmologist’s 
contention. Visual acuity decreased 
from 20/20 each eye to 20/40 OD, 
20/30 OS. What makes this case 
compelling is serial photographic 
documentation TP collected, 
meticulously tracking the progres-
sion of  his atrophic AMD (Figures 
1d – 1g).
A new plan
Undaunted by his prognosis, 
TP revised his intervention plan 
in 1998. After discontinuing all 
previous supplements, he started 
a new regimen composed solely 
of  Nutraceutical Sciences Institute 
(NSI) OcuPower (Table 1), current-
ly in its fourth formulation. After 
only eight weeks of  taking NSI 
OcuPower, TP noticed a subjective 
visual improvement OS, including 
decreased metamorphopsia and 
more vivid colour recognition. 
Vision in the right eye also im-
proved, with an estimated 30%  
reduction in metamorphopsia. 
After nine months of  taking the 
supplement, his visual acuity im-
proved from 20/40 to 20/25 OD 
and from 20/30 to 20/15 OS. A 
year later, TP no longer noticed 
metamorphopsia OU and the sco-
toma OS had markedly decreased 
in size. There were also visible 
salutary changes in his retinal im-
ages with respect to number and 
size of  drusen (Figures 1c – 1f ).
TP stated his night vision was 
never affected by the atrophic 
AMD. Neither did he feel that his 
ability to practice optometry was 
ever jeopardized. Specifically, he 
did not need to change the lighting 
in his examination rooms, nor did 
he need to modify day-to-day pro-
cedures, such as performing direct 
ophthalmoscopy.   
In November 2003, TP added an 
omega-3 supplement to his NSI 
OcuPower regimen after reading 
Background: Age-related macular 
degeneration (AMD) is the leading 
cause of blindness in ageing western 
societies and accounts for greater 
than 50% of all US visual disability. This 
report describes the 25-year history 
of a 66-year-old optometrist who has 
successfully endured AMD. 
Case Report: Visual acuity and serial 
retinal photographs from 1983 to 2009 
as various nutritional modalities and 
non-dietary lifestyle changes were 
introduced. After starting lutein-based 
nutritional supplements beginning at 
approximately 15 years from diagnosis, 
the optometrist’s Snellen visual acuity 
improved in his right eye from 20/40 to 
20/25 with a subjective improvement 
in distortion, but eventually 
regressed to 20/70-20/80 with some 
increase in metamorphopsia. The 
left eye, initially 20/30, improved to 
20/15 and has remained stable at 
20/20 with complete resolution of 
metamorphopsia and near complete 
resolution of a parafoveal scotoma. 
Fundus photographs demonstrate a 
reduction in soft and hard drusen count 
over time in each retina and possible 
parafoveal repigmentation of atrophic 
areas with later addition of higher dose 
zeaxanthin.  
Conclusions: AMD is a nutrition-
responsive disease. The carotenoids, 
lutein and zeaxanthin appear to 
be particularly robust therapeutic 
components of nutritional supplement 
formulations.
Key words:  age-related macular 
degeneration, lutein, zeaxanthin
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about the beneficial effects of  es-
sential fatty acids in slowing AMD 
progression.7 He also started 
taking a mitochondrial support 
supplement, called Phototrop, con-
taining 10 mg coenzymeQ10, 390 
mg omega-3 and 100 mg acetyl 
l-carnitine. Phototrop’s combina-
tion was shown to improve visual 
functioning in a clinical research 
study.8,9
Bolstered by his visual and fun-
duscopic improvements, TP added 
EyePromise, containing high-dose 
zeaxanthin, to round out his sup-
plementation regimen in May 2004 
after emerging research suggested 
that this foveal carotenoid may 
play an important role in central 
macular health.4,5,6  Photos taken in 
August 2005 (Figure 1g) and Febru-
ary 2008 (Figure 1h) demonstrated 
a dramatic decrease in drusen OU, 
possibly attributed to his regimen 
of  NSI OcuPower, EyePromise, 
Phototrop and omega-3 supple-
ments (Table 2). The drusen were 
smaller and fainter, and an en-
couraging “re-pigmentation of  the 
atrophic areas” was noted by TP 
when evaluating his own fundus 
photos. Unfortunately, visual 
acuity in his right eye regressed 
to 20/40. The left eye however, re-
mained stable at 20/15. Strikingly, 
no metamorphopsia was present.
The latest photos, from Febru-
ary 2009 (Figure 1g), 11 years after 
adding carotenoids, show further 
significant reduction of  pre-exist-
ing drusen, with some persistent 
geographic atrophy now affect-
ing the fovea in the right eye. TP 
noted increasing metamorphopsia 
OD, but no metamorphopsia OS, 
RIGHT EyE LEFT EyE
 1a : 1983 – First diagnosis
1b : 1988 – 5 years later
 1c : 1/23/98 -- Carotenoids 
Figure 1 – (a – c) 
Baseline bilateral fundus photographs of  optometrist, TP, taken in 1983 (1a, age 41) 
and 1988 (1b, age 46), prior to nutritional supplementation with NSI OcuPower®, 
Phototrop® and EyePromiseTM. Serial fundus photographs (1c-1g), including before 
the start of  lutein (1c) and zeaxanthin (1e) based nutritional supplementation.
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with acuities of  20/70- OD and 
20/20 OS. No significant cataract 
or other media opacity was found 
at the February 2009 visit.
Other dietary & non-dietary 
lifestyle modifications
TP’s nutritional regimen didn’t 
stop with the addition of  the 
supplements noted above. In 1998 
he began eating wolfberries (goji 
berries), another source of  zeaxan-
thin, daily. He also consumed more 
kale, collard greens, turnip greens, 
spinach, and mustard greens – all 
prime sources of  lutein to elevate 
his macular pigment optical densi-
ty.10 In December 2003, he added a 
combination bioflavonoid capsule, 
containing grape seed, green tea 
and red wine extract taken twice 
daily after reading evidence that 
these components may contribute 
to lower cholesterol levels and 
better retinal pigment epithelial 
(RPE) function, which in turn may 
slow the progression of  AMD.11 
Additionally, TP increased his 
intake of  oily fish, such as salmon 
and sardines, to raise his omega-3 
level. He has avoided overcooked 
foods, especially overcooked 
vegetables.12 He has limited intake 
of  commercial hydrogenated or 
partially-hydrogenated oils, known 
to dramatically increase the risk of  
cardiovascular disease13 and associ-
ated with late AMD.14
TP is a non-smoker, which is 
beneficial in light of  the Beaver 
Dam Eye Study in the US, the Blue 
Mountain Eye Study in Australia, 
and Rotterdam Study in the Neth-
erlands, which all found a signifi-
cant association between smoking 
and AMD.11 He controls his weight 
through routine exercise, which is 
also important because lower body 
mass index (BMI) and increased 
physical activity have been shown 
to decrease the rate of  progression 
to advanced forms of  AMD.15 TP 
wears ultraviolet/blue-light block-
ing sunglasses to protect his eyes 
when outdoors.16,17  
Figure 1 – (d –e) 
RIGHT EyE LEFT EyE
 1d : 1/26/00
 1e : 8/5/2003 
1f : 8/18/05 
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Discussion
We have presented in a sense the 
un-natural/natural history of  
AMD in a practicing optometrist 
over a 25-year period. Serial retinal 
photos, with introduction of  carot-
enoids in 1998, indicate a progres-
sive decrease in the number and 
size of  drusen and atrophic areas 
in both of  TP’s retinas. Despite a 
recent increase in metamorphopsia 
and decrease in acuity OD, TP’s 
visual acuity has remained stable 
OS at 20/20, and his central visual 
fields remain largely intact. TP only 
recently retired from his private 
optometric practice in Norway, 
Maine, where he performed com-
prehensive eye care for 44 years 
until January 2010, when he retired 
at the age of  67.
When originally released, NSI 
OcuPower contained only 1mg of  
lutein. Lycopene was added in the 
second formulation. In the third 
formulation, lutein concentration 
was increased to 10mg. In the 
fourth formulation 500mcg of  
zeaxanthin was introduced. This 
is the version of  NSI OcuPower 
(Table 1) that was evaluated during 
the LAST study.2 A newer formu-
lation is now available, now under 
the name NSI Synergy OcuPower 
Advanced. Carotenoids appear to 
be specifically important in this 
case. Lutein, an oxy-carotenoid, is 
believed to protect the macula by 
blocking blue light which helps to 
improve contrast sensitivity in cer-
tain situations18,19, while reducing 
glare disability.20 It is believed to 
function as an antioxidant, improv-
ing photo-stress recovery time and 
providing structural integrity to 
photoreceptors by its conversion 
to meso-zeaxanthin.10 Patients 
with AMD have less macular lutein 
than those without the disease, as 
determined through autopsy and 
in vivo measurements, and macular 
lutein decreases with aging, smok-
ing and obesity – the three major 
risk factors for AMD.11,15 Using 
heterochromic flicker photometry, 
the LAST study demonstrated that 
lutein supplementation increased 
mean MPOD by 36% in the study 
group that received 10mg lutein 
only, and by 43% in the group 
receiving the multi-nutrient NSI 
OcuPower supplement. Snellen 
visual acuity and contrast sensitiv-
ity also improved statistically. Ad-
ditionally, some study participants 
even experienced a subjective 
decrease in Amsler grid metamor-
phopsia and their scotoma(s).2
The authors of  this paper 
conclude that future optometry 
practice should include some 
rudimentary measurement of  
glare recovery (in seconds) as well 
as some measure of  low contrast 
vision assessment, i.e. 10% low 
contrast screening evaluation to 
assess photoreceptor/RPE health. 
In this case, such data would have 
provided a metric for follow-
ing subjective reports and more 
precisely defined the results of  
multiple therapeutic interventions. 
Notably TP had AMD at the early 
age of  41. Glare recovery and 
contrast sensitivity assessment 
would be particularly useful for all 
patients older than for example, 50 
years of  age. Unfortunately in this 
case, only traditional Snellen visual 
acuity (circa 1862) and Amsler grid 
(1895) are available. Nonetheless, 
although we cannot prove causality 
with a single case report, the reti-
nal photographs presented within 
this report appear to demonstrate 
a dynamic disease process ame-
nable to nutritional intervention. 
Figure 1 – ( g) 
RIGHT EyE LEFT EyE
 1g : 1g 02/06/09 (11 years)
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Table 2 – Visual and ophthalmic timeline for TP. 
DATE
(d/m/y)




1983 TP diagnosed with atrophic 




1983-1987 TP taking Ocuvite, Ocuvite Extra, 
ICAPS, ICAPS Plus, vitamin E, rose 
hip and Centrum
NC NC NC
1988 Fundus photo taken Increasing 
drusen OU
NC NC
9/1997 TP performs HVF and finds small 
parafoveal scotoma OS
NC NC OD, OS




2/1998 TP discusses fundus photos with 
ophthalmologist, begins taking 
OcuPower and d/c’s all other 
supplements.
NC 20/40 OD, 
20/30 OS
NC







8/3/2000 2.5-year fundus photo NC NC NC
8/5/2003 5.5-year fundus photo NC NC NC
11/2003 TP begins taking Phototrop and 
Omega-3 supplement.
NC NC NC
12/2003 TP begins taking bioflavinoid 
capsule.
NC NC NC
5/2004 TP begins taking EyePromise. NC NC NC
















Legend: NC – no change, d/c - discontinue
